Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: levodopa/carbidopa Clear all
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

NCT00789672
View directory record Official record
Conditions
Amblyopia
Interventions
levodopa/carbidopa, patching
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Phase 4 Interventional

Dopaminergic Therapy for Anhedonia - 2

NCT06075771
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Not listed No phase listed Observational

Substance Abuse Pre-Treatment Screening Study

NCT00439049
View directory record Official record
Conditions
Cocaine Abuse, Cocaine Dependence, Opiate Dependence, Alcohol Dependence, Substance Abuse
Interventions
modafinil, d-amphetamine, L-Dopa, Naltrexone
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 23, 2026, 3:43 PM EDT
Terminated Phase 4 Interventional Results available

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

NCT02549573
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms
Interventions
APOKYN, Physical Therapy
Drug · Behavioral
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569
View directory record Official record
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 23, 2026, 3:43 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

NCT03243552
View directory record Official record
Conditions
ASD
Interventions
L-DOPA versus Placebo, Social Skills Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 30 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 3:43 PM EDT
Terminated Phase 2 Interventional Results available

Vision Response to Dopamine Replacement

NCT01663935
View directory record Official record
Conditions
Albinism, Oculocutaneous Albinism
Interventions
Levodopa/carbidopa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
3 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

NCT01171313
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 1 Interventional

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

NCT03374917
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sun City, Arizona • Loma Linda, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional Results available

Levodopa for the Treatment of Residual Amblyopia

NCT01190813
View directory record Official record
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

NCT00715520
View directory record Official record
Conditions
Stroke
Interventions
Transcranial Magnetic Stimulation (TMS), Carbidopa-Levodopa, Methylphenidate, Amphetamine Sulfate, Placebo, Sham Transcranial Magnetic Stimulation (TMS), Transcranial Magnetic Stimulation (TMS) Training
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 23, 2026, 3:43 PM EDT
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 3 Interventional

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

NCT00203177
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, rasagiline mesylate 1.0 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

NCT00219284
View directory record Official record
Conditions
Parkinson's Disease With End of Dose Wearing Off
Interventions
Carbidopa/levodopa/entacapone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Fullerton, California • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 1 Interventional

Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

NCT05708274
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

NCT06587217
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 3:43 PM EDT
Suspended Phase 2Phase 3 Interventional

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 23, 2026, 3:43 PM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 3:43 PM EDT
Completed No phase listed Observational

Opicapone Treatment Initiation Open-Label Study

NCT04787965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 23, 2026, 3:43 PM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

NCT00456794
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 23, 2026, 3:43 PM EDT